A Randomized, Positive and Placebo-Controlled Trial to Evaluate the Effects of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

Rain Oncology Inc1 site in 1 country6 target enrollmentStarted: April 17, 2023Last updated: August 8, 2023

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 1
Status: Terminated
Sponsor: Rain Oncology Inc
Enrollment: 6
Locations: 1
Primary Endpoint: Number of participants with adverse events (AEs)

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

This will be a Phase 1, single-center, 2-part study in healthy subjects. Parts 1 and 2 need to be conducted in sequential order.

Detailed Description

Part 1 will enroll up to 3 cohorts of 6 healthy adult subjects to receive a single dose. The total duration of participation from the Screening visit to the follow-up will be up to 7 weeks (up to 45 days).

Part 2 of this study will randomize approximately 32 subjects. The total duration of participation from the Screening visit to the follow-up will be up to 8 weeks (up to 55 days).

Study Design

Study Type: Interventional
Allocation: Randomized
Intervention Model: Sequential
Primary Purpose: Treatment
Masking: Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages: 18 Years to 55 Years (Adult)
Sex: All
Accepts Healthy Volunteers: Yes

Inclusion Criteria

•Is capable of understanding informed consent and is willing and able to provide written informed consent.
•Is willing to comply with all protocol procedures.
•Healthy, male, nonsmoking (for at least 90 days) subjects from 18 through 55 years of age, inclusive, at Screening, and healthy, female, nonsmoking (for at least 90 days) subjects of nonchildbearing potential from 18 through 55 years of age, inclusive, at Screening.
•Body weight > 50 kg, body mass index between 18.0 and 30 kg/m2, inclusive.

Exclusion Criteria

•Past or present clinically relevant systemic disease as judged by the Investigator including, but not limited to, clinically relevant medical abnormalities such as psychiatric, neurologic, pulmonary, respiratory, cardiac, gastrointestinal, genitourinary, renal, hepatic, metabolic, endocrinologic, hematological, or autoimmune disorders making implementation of the protocol or interpretation of the study results difficult, or that would put the subject at risk by participating in the study in the opinion of the Investigator.
•History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
•Knowledge of any kind of cardiovascular disorder/condition/procedure known to increase the possibility of QT prolongation or a history of additional risk factors for torsade de pointes (eg, heart failure, hypokalemia, hypomagnesemia, congenital long QT syndrome, or family history of long QT syndrome, or Brugada syndrome), or cardiac conduction disorders.
•Resting supine systolic blood pressure greater than 140 mm Hg; resting supine diastolic blood pressure greater than 90 mm Hg at Screening or Day -
•Blood pressure measurements may be repeated once at the discretion of the Investigator.
•Resting supine HR less than 45 beats per minute or greater than 100 beats per minute at Screening or Day -1 (may be repeated once at the discretion of the Investigator). Minor deviations are acceptable if considered to be of no clinical significance by the Investigator.
•Abnormal 12-lead ECG at Screening or Day -1 (a single repeat is allowed), including:
•QTcF > 450 msec
•QRS > 110 msec
•PR > 200 msec
•Second or third-degree atrioventricular block
•Any rhythm other than sinus rhythm, which is interpreted by the Investigator to be clinically significant at Screening or Day -
•Dosing in another clinical trial within the last 30 days (or 5 half-lives, whichever is longer) prior to Day -
•Family history of unexplainable sudden death at < 50 years of age.
•History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations, clinically significant head injury, or near drowning with hospital admission.
•Known allergic reactions to moxifloxacin (for Part 2 only) or any study medication or history of tendonitis or tendon rupture as a result of moxifloxacin or any other quinolone type drug use (for Part 2 only).

Arms & Interventions

A = Placebo (negative control)

Placebo Comparator

Dosage Form: Capsules

Route of Administration: Oral

The placebo and milademetan will be identical in appearance.

Intervention: Placebo (Drug)

B = Moxifloxacin (positive control)

Active Comparator

Dosage Form: Tablets

Route of Administration: Oral

Dosage: 400 mg

Intervention: Moxifloxacin (positive control) (Drug)

C = Milademetan

Experimental

Drug: Milademetan

Dosage:

Part 1: 300, 330, 360 mg. Part 2: 260 mg single oral dose or higher, as determined in Part 1.

Intervention: Milademetan (Drug)